Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Innobation Bio Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, creating separate prosecution channels.
STOICA, ELLY GERALD is the busiest examiner, with 1 pending matter. Counsel should coordinate the overall claim strategy while tailoring each response to the relevant examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791028 | COMPANION DIAGNOSIS BIOMARKER COMPOSITION AND COMPANION DIAGNOSIS KIT CONTAINING SAME | DICKINSON, PAUL W | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575494 | ANTIBODY SPECIFIC FOR MESOTHELIN AND USES THEREOF | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575494 | ANTIBODY SPECIFIC FOR MESOTHELIN AND USES THEREOF | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 17791028 | COMPANION DIAGNOSIS BIOMARKER COMPOSITION AND COMPANION DIAGNOSIS KIT CONTAINING SAME | DICKINSON, PAUL W | 1618 | §101§102§112 | Final Rejection | 7d | Pending | Jul 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnobation Bio Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Elly Gerald Stoica has the most, with 1 of Innobation Bio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
